K 134

Drug Profile

K 134

Alternative Names: K-134; OPC-33509

Latest Information Update: 21 Aug 2015

Price : $50

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer Kowa
  • Class Antiplatelets; Antithrombotics; Organic chemicals; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Arteriosclerosis obliterans

Most Recent Events

  • 19 Aug 2015 Phase-II development is ongoing in USA and Japan
  • 27 Aug 2014 The primary endpoint was not met in a phase IIb trial for Arteriosclerosis obliterans in Japan
  • 16 Nov 2011 Phase II development is ongoing in USA & Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top